J Biomed Mater Res A, 2014
Evaluation of an established pericardium patch for delivery of mesenchymal
stem cells to cardiac tissue
Vashi, AV; White, JF; McLean, KM; Neethling, WM; Rhodes, DI; Ramshaw, JA; Werkmeister, JA The present study has evaluated a commercial pericardial material for its capacity to assist as a natural extracellular matrix (ECM) patch for the delivery and retention of mesenchymal stem cells for cardiac repair. The repair of cardiac tissue with cells delivered by an appropriate bioscaffold is expected to offer a superior, long-lasting treatment strategy. The present material, CardioCel®, is based on acellular pericardium that has been stabilized by treatments, including a low concentration of glutaraldehyde, that eliminate calcification after implantation. In the present study, we have assessed this material using human bone marrow mesenchymal stem cells at various cell densities under standard, static cell culture conditions. The initial seeding densities were monitored to evaluate the extent of cell attachment and cell viability, with subsequent cell proliferation assessed up to 4 weeks using an MTS assay. Cell morphology, infiltration, and spreading were tracked using scanning electron microscopy and phalloidin staining. The efficacy of long-term cell survival was further assessed by examining the extent and type of new tissue formation on seeded scaffolds at 70 days; both type I and type III collagens were present in fibrillar structures on these scaffolds indicating that the seeded stem cells had the capacity to differentiate into collagen-producing cells necessary to repair damaged ECM. These data show that the CardioCel® scaffold is an appropriate substrate for the stem cells and has the potential to both retain seeded stem cells and to act as a template for cell propagation and new tissue formation. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2014. Copyright © 2014 Wiley Periodicals, Inc. Type: Journal article PMID: 25266083 | DOI Full Text (full-text online)
- Forums
- ASX - By Stock
- Cardiocel for stem cell article
J Biomed Mater Res A, 2014 Evaluation of an established...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.14 |
Change
0.000(0.00%) |
Mkt cap ! $277.7M |
Open | High | Low | Value | Volume |
$13.33 | $13.91 | $13.14 | $302.2K | 22.46K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 299 | $13.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.49 | 35 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 299 | 13.140 |
4 | 2791 | 13.000 |
2 | 67 | 12.900 |
1 | 1000 | 12.500 |
1 | 1500 | 11.610 |
Price($) | Vol. | No. |
---|---|---|
13.490 | 35 | 1 |
13.500 | 750 | 1 |
14.100 | 100 | 1 |
14.440 | 25 | 1 |
14.500 | 60 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online